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The Retinoblastoma-Histone Deacetylase 3
Complex Inhibits PPAR
and Adipocyte Differentiation
of preadipocytes. Consequently, RB has been found to
be hyperphosphorylated and, thus, inactive in these
early stages of adipogenesis (Richon et al., 1997). In
the later stages, RB positively regulates adipogenesis
participating in the cell cycle exit required for terminal
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France Since both PPAR and RB are major regulators of
cell proliferation and differentiation, a crosstalk between
PPARand RB signaling might operate during adipocyte
differentiation. We show here that RB recruits histoneSummary
deacetylase 3 (HDAC3) to PPAR target genes. Disrup-
tion of the PPAR-RB-HDAC3 complex by phosphoryla-The retinoblastoma protein (RB) has previously been
tion of RB or inhibition of HDAC3 activity results in theshown to facilitate adipocyte differentiation by induc-
activation of PPAR, translating to an increase in adipo-ing cell cycle arrest and enhancing the transactivation
genesis.by the adipogenic CCAAT/enhancer binding proteins
(C/EBP). We show here that the peroxisome prolifera-
tor-activated receptor  (PPAR), a nuclear receptor Results and Discussion
pivotal for adipogenesis, promotes adipocyte differen-
tiation more efficiently in the absence of RB. PPAR To analyze the effects of RB on adipogenesis, we com-
pared the efficacy of RB/or RB/MEFs to differen-and RB were shown to coimmunoprecipitate, and this
PPAR-RB complex also contains the histone deacet- tiate into adipocytes. A standard differentiation mixture
(MDI) induced significant lipid accumulation, as as-ylase HDAC3, thereby attenuating PPAR’s capacity
to drive gene expression and adipocyte differentiation. sessed by Oil Red O staining, in RB/, but not in
RB/, MEFs (Figure 1A). These differences were notDissociation of the PPAR-RB-HDAC3 complex by RB
phosphorylation or by inhibition of HDAC activity stim- the consequence of decreased expression of PPAR
(Figure 1B). Interestingly, when the PPAR agonist rosig-ulates adipocyte differentiation. These observations
underscore an important function of both RB and litazone was added to the differentiation mix, a striking
increase in lipid accumulation was observed in RB/HDAC3 in fine-tuning PPAR activity and adipocyte
differentiation. MEFs, which now became even more pronounced than
in rosiglitazone-treated RB/ cells (Figure 1A). Fur-
thermore, the adipocyte-specific marker aP2 was moreIntroduction
robustly induced in RB/ than in RB/ MEFs after
rosiglitazone (Figure 1B).One of the first events following hormonal induction of
These data suggested that RB inhibited PPAR activ-differentiation of preadipocytes is a reentry of these
ity and, hence, negatively regulates rosiglitazone-stimu-growth-arrested preadipocytes into the cell cycle. After
lated adipogenesis. This hypothesis was further testedseveral rounds of clonal expansion, these cells arrest
by transient transfection experiments in RB/ MEFsagain and undergo terminal adipocyte differentiation (re-
with PPAR and RB expression vectors and a PPAR-viewed in Fajas et al., 2001). Blocking cell cycle reentry
responsive luciferase reporter (PPRE-TK-Luc). A 7-foldwith DNA synthesis inhibitors prevents adipocyte differ-
induction of luciferase activity was observed upon trans-entiation, suggesting that active cell cycle machinery is
fection of PPAR in the presence of rosiglitazone. Thisrequired for the differentiation process (Richon et al.,
induction was significantly attenuated by cotransfection1997). The retinoblastoma protein RB, which is a nega-
of RB (Figure 1C). To further demonstrate that RB nega-tive regulator of the cell cycle, plays a dual role in adipo-
tively influences PPAR activity, we used a Gal4-respon-cyte differentiation. During clonal expansion, RB plays
sive luciferase reporter (UAS-TK-Luc) and a plasmid ex-a negative role by inhibiting reentry into the cell cycle
pressing a BD Gal4-PPAR DE fusion protein, which
contains the Gal4 DNA binding domain fused to the4Correspondence: auwerx@igbmc.u-strasbg.fr
ligand binding domain (DE) of PPAR. Cotransfection5These authors contributed equally to this work.
of BD Gal4-PPAR DE with UAS-TK-Luc resulted in a6Present address: Endocrinologie Mole´culaire et Cellulaire des Can-
cers, 60 rue Navacelles, 34090 Montpellier, France. 2-fold increase in luciferase activity, which was further
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Figure 1. Rosiglitazone Enhances Adipocyte Differentiation in the Absence of RB
(A) Micrographs of Oil Red O-stained RB/ and RB/ MEFs 10 days after the induction of differentiation. Cells in the upper panel were
challenged with a standard adipogenic regimen (MDI). Cells in the lower panel were induced to differentiate with MDI, to which 106 M
rosiglitazone (rosi) was added. In all future experiments the same concentration of rosiglitazone was used.
(B) Expression of adipocyte marker genes analyzed by multiplex RT-PCR in RB/ and RB/ MEFs treated (rosi) or not (cont) with MDI in
the presence of rosiglitazone for 3 days.
(C) Activity of the PPRE-TK-Luc reporter transfected in RB/ MEFs with expression vectors for PPAR, RB, or both together. Experiments
were performed either in the absence (open bars) or presence of rosiglitazone (black bars). No effect on -gal acivity was observed. Fold-
induction relative to the basal condition is shown.
(D) Activity of the UAS-TK-Luc reporter transfected in RB/ MEFs with an expression vector for a BD Gal4-PPAR DE fusion protein alone
or in combination with increasing amounts of an RB expression vector. The experiments were normalized for -gal activity.
(E) Expression of PPAR and RB during differentiation of 3T3-L1 cells into adipocytes was analyzed by immunoblotting. Phosphorylated RB
(ppRB) is the slower-migrating band relative to hypophosphorylated RB (pRB).
enhanced up to 4.5-fold on addition of rosiglitazone only PPAR activity, but also PPAR expression, is re-
duced in fully differentiated adipocytes, suggestive of(Figure 1D). Increasing concentrations of RB dose de-
pendently decreased rosiglitazone-dependent PPAR a less important role of PPARat that stage (Rosenbaum
and Greenberg, 1998).activity (Figure 1D), demonstrating that RB inhibits
PPAR. To test whether the inhibition of PPAR activity in the
presence of RB was the consequence of an interactionConsistent with a negative role of RB during adipocyte
differentiation, RB was phosphorylated between days 2 between PPAR and RB, nuclear extracts from rosiglita-
zone-treated 3T3-L1 cells during (day 4) or after (day 8)and 6 of 3T3-L1 differentiation (Figure 1E and Reichert
and Eick, 1999). At day 8, when cells were fully differenti- differentiation into adipocytes were immunoprecipitated
with an anti-PPAR antibody. A 110 kDa protein wasated, RB was mostly hypophosphorylated again. The
presence of phosphorylated and, thus, inactive RB at a recognized in the immunoprecipitates by an anti-RB an-
tibody, indicating that RB interacted directly in vivo withcritical period during the differentiation process sug-
gested that hypophosphorylated active RB negatively PPAR after adipocyte differentiation (Figure 2A, lane
5, day 8). This RB-PPAR complex was not present ininfluences PPAR activity. In line with this, other groups
have previously reported the presence of hyperphos- actively differentiating cells (Figure 2A, lane 4, day 4).
According to the transfection data in Figures 1C andphorylated RB between days 1 and 5 (Hansen et al.,
1999; Shao and Lazar, 1997), a time when maximal 1D, the lack of interaction of PPAR with RB at day 4
of differentiation should increase PPAR activity. In linePPAR activity is required to boost adipocyte differenti-
ation, and the reoccurence of hypophosphorylated RB with this hypothesis, the expression of lipoprotein lipase
(LPL), a PPAR target gene, was induced by rosiglita-in fully differentiated adipocytes (between days 6 and
8) (Hansen et al., 1999; Shao and Lazar, 1997), when zone in differentiating 3T3-L1 cells (Figure 2B, day 4),
but not in fully differentiated 3T3-L1 adipocytes (FigurePPAR activity is no longer required. Interestingly, not
PPAR, RB, and HDAC
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Figure 2. PPAR Interacts with RB
(A) Coimmunoprecipitation of PPAR and RB from 3T3-L1 cells during (day 4) or after adipocyte differentiation (day 8) in the presence of
rosiglitazone. Extracts are immunoprecipitated with either an anti-PPAR antibody (PPAR, lanes 4–5) or preimmune serum (Mock, lane 1)
and revealed by an anti-RB antibody. One fifth of the input is shown as a control (lanes 2 and 3).
(B) Semi-quantitative RT-PCR showing expression of the mouse LPL and GAPDH mRNA in either differentiating (day 4) or differentiated (day
8) 3T3-L1 cells. Relative expression of LPL mRNA in rosiglitazone-treated versus untreated cells is indicated as fold induction.
(C) GST pull-down assay showing the interaction of PPAR with hypophosphorylated RB. Nuclear extracts from rosiglitazone-treated RB/
MEFs were incubated with Sepharose-bound GST-PPAR fusion protein or GST alone. Bound proteins were immunoblotted with an anti-RB
antibody, which recognizes all forms of RB. Hypo- (pRB) and hyperphosphorylated (ppRB) RB is indicated. One-tenth of the input demonstrated
the presence of both forms of RB.
(D) GST-pull down assay showing ligand-dependent PPAR-RB interaction. GST alone or GST-RB protein (aa 379–928) was incubated with
the hPPAR DE protein (residues 203–477) in the presence of increasing amounts of rosiglitazone. Bound protein was visualized with an anti-
PPAR antibody.
(E) GST pull-down assays with in vitro-translated 35S-radiolabeled PPAR protein and the indicated GST-RB constructs or GST alone. A
scheme of the distinct RB domains is shown.
(F) GST pull-down assays with nuclear extracts from RB/ or RB/ MEFs treated with rosiglitazone for 3 days and GST-PPAR fusion
proteins or GST alone. Proteins were immunoblotted with an anti-RB antibody. A scheme of the domain structure of PPAR is shown.
2B, day 8). This result appears to contradict previous hyper- (slow-migrating) and hypophosphorylated (fast-
migrating) RB, but only the fast-migrating form of RBdata from our laboratory demonstrating an induction of
LPL mRNA in both adipocyte cell lines and adipose was retained by GST-PPAR (Figure 2C), demonstrating
that PPAR interacts preferentially with hypophosphor-tissue in response to rosiglitazone (Schoonjans et al.,
1996). In this last study, LPL expression was, however, ylated RB.
We also determined whether ligand binding of PPARnot analyzed in fully differentiated cells, but in differenti-
ating cells (Schoonjans et al., 1996). Furthermore, in could influence the interaction between PPAR and RB.
While very little, if any, PPAR interacted with GST-RBadipose tissue, which is heterogeneous in nature and
composed of adipocytes, preadipocytes, and stromal in absence of ligand, binding of PPAR to GST-RB was
dose dependently enhanced by rosiglitazone (Figurecells, the PPAR-mediated stimulation of LPL expres-
sion in subset of cells (i.e., preadipocytes) would mask 2D). The domains in RB and PPAR that interact were
then mapped (Figures 2E and 2F). Using in vitro-trans-any repressive effect in mature adipocytes.
Inactivation of RB by phosphorylation could explain, lated 35S-radiolabeled PPAR2 and GST fusion proteins
containing distinct domains of RB, we demonstratedat least in part, the decrease of PPAR-RB interaction
and, therefore, the increase in PPAR activity required that PPAR interacted with GST-RB fusion proteins con-
taining either the three pockets (A, B, and C) or pocketsfor adipocyte differentiation. To prove that PPAR inter-
acts only with the hypophosphorylated form of RB, GST- B and C (Figure 2E, lanes 2 and 5). PPAR interacted
weakly, or not at all, with the B and A pockets of RB,PPAR DE fusion protein was incubated with nuclear
extracts from rosiglitazone-treated RB/ MEFs, and respectively (Figure 2E, lanes 3 and 4). Likewise, differ-
ent GST-fusion proteins containing either exon b andthe precipitates were immunoblotted with an anti-RB
antibody (Figure 2C). RB/ MEFs contained both the AB domain (b-AB), the AB domain (AB), or the DE
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domain of PPAR were incubated with nuclear extracts by rosiglitazone (Figure 3E). Cotransfection of RB with
from confluent RB/ or RB/MEFs, and bound pro- PPAR attenuated the induction of the reporter by rosig-
teins were immunoblotted with an anti-RB antibody (Fig- litazone. Combination of rosiglitazone with TSA, how-
ure 2F). RB was only retained by the GST-PPAR DE ever, abrogated this inhibitory effect of RB on PPAR,
fusion protein in RB/ MEFs (Figure 2F, top panel), thereby mimicking the situation where RB is absent (Fig-
which is coherent with the ligand-dependence of the ure 3E). Similar results were obtained with 4PB (data
interaction between PPAR and RB (Figure 2D). not shown). Furthermore, coincubation of confluent and
It is well established that hypophosphorylated RB serum-starved RB/ U2OS cells with rosiglitazone
binds to the cell cycle regulator E2F and either blocks and TSA resulted in a 2.5-fold induction of LPL mRNA,
activation of E2F target genes or actively represses tran- whereas no induction in LPL mRNA levels was observed
scription through recruitment of histone deacetylases upon treatment with rosiglitazone or TSA alone (Figure
(HDACs) (Brehm et al., 1998; Magnaghi-Jaulin et al., 3F). Importantly, confluent and serum-starved U2OS
1998). We next tested whether repression of PPAR cells contain hypophosphorylated and, thus, active RB
activity by RB could be mediated by recruitment of his- (data not shown), which is nonpermissive for the induc-
tone deacetylases (HDACs) in immunoprecipitation tion of LPL expression (see also Figure 2C). Interestingly,
studies. Protein extracts from COS cells transfected with treatment of TSA alone had a repressive effect on the
expression vectors for PPAR, Flag-HDAC3, and RB LPL expression (Figure 3F, lane 3). Whether this TSA-
were immunoprecipitated with either anti-PPAR or mediated repression of LPL has any physiological impli-
anti-Flag antibodies. PPAR immunoprecipitates con-
cation awaits further study. In contrast to the data in
tained both HDAC3 and RB (Figure 3A). Similarly, Flag
U2OS cells, rosiglitazone by itself increased LPL mRNA(HDAC3) immunoprecipitates contained RB and PPAR
levels by 2-fold in RB-deficient SaOS cells (data not(Figure 3A), strongly suggesting that PPAR, RB, and
shown), a situation similar to that observed in U2OSHDAC3 are part of the same protein complex in the cell.
cells treated with TSA and rosiglitazone.To obtain further proof of the crucial role of RB in this
Our results so far suggest that RB recruits HDACs tocomplex, nuclear extracts from rosiglitazone-treated
PPAR target genes to repress transcription. To obtainRB/ or RB/ MEFs were analyzed by GST pull-
experimental evidence of this, we performed anotherdown assays with a GST-PPAR DE fusion protein. Only
ChIP in U2OS cells (Figure 3G). No acetylated histonein RB/ MEFs, but not in RB/ MEFs, HDAC3 was
H4 was immunoprecipitated complexed to the LPL pro-retained by GST-PPAR (Figure 3B). HDAC1, 2, 4, or 5
moter when U2OS cells were incubated with rosiglita-could not be detected when specific antibodies were
zone alone. PPAR and HDAC3 were, however, presentused (data not shown). To assess that HDAC3 was func-
on the LPL promoter under these conditions, suggestingtional in this complex, proteins bound either to the GST
that the PPAR-RB-HDAC3 complex silenced LPL ex-or GST-PPAR were incubated with histone H4 that had
pression (Figure 3G). More HDAC3 was present uponbeen acetylated on Lys 9. Using an anti-acetylated his-
rosiglitazone treatment relative to control cells, consis-tone H4 (Lys 9) antibody, we demonstrated that histone
tent with the ligand dependence of RB recruitment toH4 was specifically deacetylated by proteins bound to
PPAR. In contrast, treatment of U2OS cells with boththe GST-PPAR, but not to GST itself (Figure 3C). When
the HDAC inhibitor, 4-phenyl butyrate (4PB), was in- TSA and rosiglitazone resulted in the disappearance of
cluded in the incubation, acetylated histone H4 re- HDAC3 from the LPL promoter. This loss of HDAC3 was
mained detectable (Figure 3C). No deacetylation activity concomitant with histone H4 acetylation, indicative of
was present in extracts from RB/ MEFs, suggesting promoter activation and consistent with the increase in
that the HDAC activity was dependent on the presence LPL mRNA seen in these U2OS cells stimulated with
of RB (data not shown). rosiglitazone and TSA (Figure 3F, lane 4). Disruption of
To demonstrate that this PPAR-RB-HDAC3 complex the HDAC3 complex by TSA was furthermore demon-
occupied PPAR-dependent promoters in vivo, we per- strated by GST pull-down assays using GST or GST-
formed a chromatin immunoprecipitation (ChIP) analysis PPAR proteins and cell extracts from COS cells trans-
of the LPL promoter in both RB/ U2OS and RB/ fected with HDAC3 and RB expression vectors. Western
SaOS cells. A 200 bp fragment of the human lipoprotein blot analysis demonstrated that HDAC3 was among the
lipase (LPL) promoter, containing the binding site of proteins retained by GST-PPAR (Figure 3H). More
PPAR (Schoonjans et al., 1996), was amplified by PCR
HDAC3 was retained when cells were incubated with
when anti-RB, anti-PPAR, or anti-HDAC3 antibodies
rosiglitazone, whereas rosiglitazone in the presence ofwere used to immunoprecipitate chromatin from rosigli-
TSA resulted in the disappearance of HDAC3 from thetazone-treated U2OS cells (Figure 3D). Although PPAR
GST-PPAR complex (Figure 3H). This result is consis-was present, HDAC3 was not detected on the LPL pro-
tent with a previous report indicating that HDAC inhibi-moter in the SaOS cells (Figure 3D). Since HDAC3 is
tors disrupted an Sp1/Sp3/HDAC1 complex on the insu-expressed in SaOS cells (data not shown), these data
lin-like growth factor binding protein 3 (IGFBP-3)further support the hypothesis that RB is required to
promoter (Choi et al., 2002).recruit HDAC3 to PPAR target genes.
We next evaluated the effects of HDAC inhibition onTo prove that the attenuation of PPAR activity by RB
3T3-L1 adipocyte differentiation. Four days after incuba-was mediated by HDACs, we tested the effects of the
tion with the MDI differentiation mix, 3T3-L1 cells didHDAC inhibitor trichostatin A (TSA) in transfection exper-
not yet accumulate significant amounts of lipids, as evi-iments in RB/MEFs. Addition of suboptimal concen-
denced by the absence of Oil Red O staining (Figuretrations of TSA (107 M) to RB/ MEFs transfected
with PPAR had a minimal effect on PPAR activation 4A, first panel). In contrast, 3T3-L1 cells incubated with
PPAR, RB, and HDAC
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Figure 3. PPAR Activity Is Modified by RB, which Recruits HDAC3 to PPAR
(A) Immunoprecipitation assay showing interaction between HDAC3, RB, and PPAR. Extracts from COS cells transfected with Flag-HDAC3,
PPAR, and RB were immunoprecipitated with anti-PPAR (lane 2), anti-Flag-HDAC3 (lane 3), or preimmune serum (Mock, lane 4) or directly
analyzed for the presence of RB, PPAR, and Flag-HDAC3 (Input, lane 1). Western blot analysis revealed the presence of RB (upper panel),
PPAR (middle panel), or HDAC3 (lower panel) in both PPAR and Flag-HDAC immunoprecipitates.
(B) GST pull-down assay showing the presence of HDAC3 in the PPAR-RB complex. Nuclear extracts of rosiglitazone-treated RB/ or
RB/ MEFs were incubated with Sepharose-bound GST-PPAR or GST alone. Bound proteins were immunoblotted with an anti-HDAC3
antibody. One-tenth of the input demonstrated the presence of HDAC3 in both cell lines (lane 1).
(C) Histone deacetylation assay. Western blot analysis, with an anti-acetylated histone H4 antibody to detect deacetylase activity, of proteins
bound by GST or GST-PPAR. Complexes brought down by the two different GST fusion proteins were incubated with acetylated histone H4
(Lys 9) in the absence or presence of 0.5 mM 4-phenyl butyrate (4PB). Half of the input was used as a control (lane 4).
(D) Chromatin immunoprecipitation (ChIP) assays demonstrating binding of RB, PPAR, or HDAC3 to the LPL promoter. Crosslinked chromatin
from rosiglitazone-treated U2OS (upper panel) or SaOS (lower panel) cells was incubated with antibodies against RB (lane 2), PPAR (lane
3), HDAC3 (lanes 4), or preimmune serum (lane 1). Immunoprecipitates were analyzed by PCR with primers specific for the human LPL
promoter.
(E) Activity generated from the PPRE-TK-Luc reporter cotransfected in RB/ MEFs with expression vectors for PPAR, RB, or both together.
Experiments were performed either without stimulation (cont) or in the presence of rosiglitazone (rosi), 107 M trichostatin A (TSA), or rosi
and TSA. Fold induction of reporter activity by rosiglitazone relative to control or TSA, respectively, is indicated.
(F) Northern blot analysis showing expression of LPL and 36B4 mRNA in U2OS cells treated for 48 hr with vehicle (cont), rosiglitazone (rosi),
TSA, or a combination of both. Fold induction is indicated.
(G) ChIP assays to analyze the presence of PPAR, HDAC3, and acetylated histones on the human LPL promoter. Crosslinked chromatin
from U2OS cells treated with vehicle (cont), rosiglitazone (rosi), TSA, or a combination of both was incubated with antibodies against PPAR
(lane 2), HDAC3 (lane 3), acetylated histone H4 (lane 4), or preimmune serum (Mock, lane 1). Immunoprecipitates were analyzed by PCR with
primers specific for the human LPL promoter.
(H) GST pull-down assay demonstrating the disruption of the interaction between PPAR and HDAC3 by TSA. COS cells were transfected
with RB and HDAC3 and treated with rosiglitazone (rosi), 107 M TSA, or TSA and rosi. Extracts were incubated with GST or GST-PPAR.
Interaction of HDAC with GST-PPAR increased in the presence of rosi and was diminished by the presence of TSA.
MDI and either of five chemically distinct HDAC inhibi- incubation with these structurally unrelated HDAC inhib-
itors (Figure 4B). 4PB and VA have been shown, respec-tors, i.e., suberoylanilide hydroxamic acid (SAHA), val-
proic acid (VA), 4PB, apicidin, or MS-276, accumulated tively, to be able to bind (Samid et al., 2000) or activate
(Lampen et al., 2001) PPAR. Therefore, we analyzedsignificant amounts of lipids and differentiated into adi-
pocytes (Figure 4A). Consistent with a stimulatory effect the capacity of the various HDAC inhibitors to displace
radiolabeled 3H-rosiglitazone bound to the GST-PPARof HDAC inhibitors on PPAR, the activity of the PPRE-
TK-Luc reporter was dose dependently increased upon DE fusion protein. 4PB (Ki of 3 mM) and, to a lesser
Developmental Cell
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Figure 4. PPAR Activity Is Restored in RB/ Cells in the Presence of HDAC Inhibitors
(A) Micrographs of confluent 3T3-L1 cells treated for 4 days with MDI differentiation mix or MDI, to which rosiglitazone (rosi), 0.2 M SAHA,
1.5 mM VA, 1.5 mM 4PB, 50 nM apicidin, or 2.5 M MS-275 was added. Cells were stained with Oil Red O. Quantification of red staining
(Adobe Photoshop 6) is indicated.
(B) Activity of the PPRE-TK-Luc reporter transfected in NIH-3T3 cells, in the absence (white bar) or presence of increasing concentrations of
rosiglitazone, SAHA, VA, 4PB, apicidin, or MS-275 (shaded bars).
(C) Radioligand displacement assay. Nonradioactive 4PB and VA compete, whereas SAHA, MS-275, and apicidin do not compete, with
3H-radiolabeled rosiglitazone for binding to GST-PPAR. Values are expressed as disintegrations per minute. Radioactivity in the presence
of cold rosiglitazone defines unspecific binding.
(D) Similar radioligand displacement assay, as in (C), performed with increasing concentrations of VA and 4PB. Ki values of both compounds
are indicated.
(E) Cofactor recruitment assay. SDS-PAGE electrophoresis showing in vitro-translated radiolabeled PPAR or ER retained by either GST or
GST-p300 fusion protein upon incubation with vehicle, ligand (either estradiol or rosiglitazone at 1 M), SAHA (5 M), VA (5 mM), 4PB (5 mM),
apicidin (1 M), or MS-275 (5 M).
extent, VA (Ki 20 mM) were able to compete for binding activation of PPAR and HDAC inhibition could contrib-
ute to their adipogenic activity.with rosiglitazone (Figures 4C–4D), demonstrating that
they are low-affinity PPAR ligands. In contrast, SAHA, The detection of a PPAR-RB-HDAC3 protein com-
plex on the promoter of well-established PPAR targetsMS-275, and apicidin did not compete with 3H-rosiglita-
zone for binding to PPAR (Figure 4C). In addition to in vivo, as well as the fact that the proadipogenic effects
of PPAR were blunted by the presence of RB, on thethis ligand binding assay, a cofactor recruitment assay
was performed with these HDAC inhibitors, stipulating one hand, and stimulated by HDAC inhibitors, on the other
hand, underscores the relevance of the repression ofthat direct PPAR ligands should facilitate cofactor re-
cruitment. Rosiglitazone stimulated the interaction of PPAR by RB and HDAC3. Complexes involved in nu-
clear receptor-mediated transcriptional repression of-GST-p300 with PPAR, whereas SAHA, apicidin, and
MS-275 did not induce such an interaction (Figure 4E). ten contain HDACs (Nagy et al., 1997). The thyroid recep-
tor, as does PPAR, specifically recruits HDAC3 (Li et4PB and VA enhanced the recruitment of p300 to PPAR
(Figure 4E), confirming that they are PPAR ligands. al., 2002). Participation of HDACs in the repressive activ-
ity of nuclear receptor is facilitated by the presence ofNone of the HDAC inhibitors facilitated p300 docking to
the estrogen receptor  (ER; Figure 4E), indicating that other corepressors, such as the silencing mediator of
retinoic and thyroid receptors (SMRT) or the nuclearbinding of VA and 4PB to PPARwas specific. In combi-
nation, these data prove that HDAC inhibitors, such as receptor corepressor (N-CoR). Furthermore, corepres-
sors such as SMRT and N-CoR are required for theSAHA, apicidin, and MS-275, which do not bind to
PPAR, stimulate its proadipogenic activity by inhibiting activation of HDAC3 in such complexes (Guenther et
al., 2001). It is therefore tempting to speculate that RBthe repressive PPAR-RB-HDAC3 complex. Further-
more, in the case of VA and 4PB, both direct ligand fulfills such a corepressor role for PPAR.
PPAR, RB, and HDAC
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The fact that ligand binding stimulates recruitment of inactive RB during adipocyte differentiation (Figure 1E
RB by PPAR suggests that RB, unlike most typical and Reichert and Eick, 1999). Finally, in vivo support for
nuclear receptor corepressor complexes, might specifi- a more complex role of RB in adipocyte differentiation
cally reduce ligand-induced responses. The attenuation is provided by the observation that transgenic mice over-
of the activity of ligand-bound PPAR only occurs with expressing RB show a significant decrease (by 43%) of
hypophosphorylated, but not with hyperphosphory- paraovarian fat mass (Nikitin et al., 2001)
lated, RB. Under conditions where optimal PPAR activ- In summary, our data demonstrate that RB interacts
ity is required, such as during adipogenesis, RB is mainly with PPAR and that this interaction results in the re-
phosphorylated and, hence, dissociates from PPAR. cruitment of HDAC3 to PPAR target promoters. Similar
The fact that the interaction of PPAR and RB is regu- to their role in the control of the transcription factor
lated through both the status of PPAR and RB actually E2F1, RB and HDACs inhibit PPAR activity, thereby
allows fine-tuning of PPAR. This so-called “double gat- modulating its effects on adipocyte differentiation.
ing” of PPAR activity, by both ligand binding to PPAR
and phosphorylation of RB, also allows distinct signaling Experimental Procedures
pathways to convergently affect target gene expression.
MaterialsThese observations led us to hypothesize that PPAR
Rosiglitazone was provided by Carex S.A. (Strasbourg, France). 3H-can exist in several complexes with distinct activity.
radiolabeled rosiglitazone was purchased from ARC (St. Louis, MO).First, PPAR can occur as an inactive and unliganded
All chemicals, unless stated otherwise, were purchased from Sigma
receptor. Second, ligand-bound PPAR can be tran- (St. Louis, MO). SAHA was purchased from Biomol (Buttler Pike,
scriptionally repressed through complex formation with PA), and MS-275 and apicidin were from Calbiochem (San Diego,
hypophosphorylated RB and HDAC3. Finally, ligand- CA). Anti-PPAR E-8 antibody was purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). The anti-RB antibody (G3-245) wasbound PPAR can, consequent to RB phosphorylation
from Pharmingen (San Diego, CA), and the acetylated histone H4or HDAC inhibition, release RB and HDAC3 and actively
(Lys 9) peptide, anti-acetylated histone H4 (Lys 9) antibody, andrecruit coactivators, enabling transcription. Hypophos-
anti-HDAC3 antibodies were from Upstate Biotechnology (Lakephorylated RB can therefore be seen as an actual core-
Placid, NY).
pressor, which, unlike most corepressors, interacts with
a ligand-bound receptor. Interestingly, recruitment of a
Plasmids, Oligonucleotides, and Proteins
corepressor to a ligand-bound receptor is not unique GST-RB, GST-p300, GST-PPAR DE, UAS-TK-Luc, PPRE-TK-Luc,
to PPAR and RB, since a similar repression of ligand- BD Gal4-PPAR DE, cDNAs for aP2, LPL, 36B4, and the PPAR and
induced receptor activation has been reported for re- RB expression vectors were all described previously (Fajas et al.,
2000; Rocchi et al., 2001). Oligonucleotides used in the ChIP assayspressor complexes, such as those coordinated by the
to amplify the human LPL promoter are 5-GGGCCCCCGGGTAreceptor interacting protein (RIP140) (Cavailles et al.,
GAGTGG-3 and 5-CACGCCAAGGCTGCTTATGTGACT-3. His6-1995; Treuter et al., 1998), the SMRT/HDAC1-associated
tagged hPPAR LBD (residues 203–477) was produced in E. coli
repressor protein (SHARP) (Shi et al., 2001), the tran- BL21 (DE3) with the pET15b expression plasmid (Novagen, Madison,
scription intermediary factor 1 (TIF-1) (Beckstead et al., WI) and purified by immobilized metal ion affinity chromatography on
2001), the metastasis-associated protein 1 corepressor a Co2-loaded HiTrap Chelating column (Pharmacia, Orsay, France),
and then gel filtration chromatography was performed on a HiLoad(MTA) (Mazumdar et al., 2001), and the small hetero-
Superdex 100 column (Pharmacia).dimer partner SHP (Johansson et al., 1999).
RB has been previously shown to facilitate the differ-
Cell Culture, Protein Extracts, and Transfectionsentiation of preadipocytes and MEFs into adipocytes
MEFs and 3T3-L1, U2OS, and SaOS cells (ATCC, Manassas, VA)(Chen et al., 1996a; Classon et al., 2000; Higgins et al.,
were grown in DMEM with 10% fetal calf serum. In some differentia-1996), which seems at odds with our results. This appar-
tion studies MDI (0.5 mM 3-Isobutyl-1-methylxanthine, 10 g/ml
ent paradox can be explained by a dual effect of RB in insulin, and 1 M dexamethasone) was added for 2 days. From
adipocyte differentiation. On the one hand, RB mediates day 3 on, cells were incubated with 10 g/ml insulin, and 106 M
the cell cycle arrest required for adipocyte differentiation rosiglitazone was added when stated. Oil Red O staining (Rocchi
(Higgins et al., 1996). Furthermore, it was suggested et al., 2001) and nuclear and whole-cell extracts were prepared as
described. Lipofectamine (Life Technologies, Rockville, MD) wasthat enhanced transcriptional activation of C/EBP family
used to transfect cells, and luciferase and -gal activity was mea-members accounted for the adipogenic role of RB (Chen
sured as described (Rocchi et al., 2001).et al., 1996b), an observation questioned by the demon-
stration that C/EBP plays a subordinate role to PPAR
Pull-Down, Coimmunoprecipitation, Chromatinin adipogenesis (Rosen et al., 2002). Such a positive role
Immunoprecipitation (ChIP), and Deacetylation Assaysof RB on cell cycle arrest and differentiation would,
In vitro translation of pSG5-PPAR was performed with 35S-methio-
however, explain the decrease in adipogenesis ob- nine (Amersham, Orsay, France) in a TNT-coupled reticulocyte lysate
served in RB/ MEFs by a standard differentiation (Promega, Madison, WI). Pull-down, immunoprecipitation assays
protocol. On the other hand, RB can attenuate PPAR and ChIP assays were performed as described (Fajas et al., 2002).
Histone deacetylation assays were performed by incubating GST-activity by recruiting HDAC3 and, therefore, inhibit adi-
bound or GST-PPAR-bound proteins from nuclear extracts with 2pocyte differentiation. This explains the robust increase
g of acetylated histone H4 for 3 hr at 21	C in HDAC buffer (10 mMin lipid incorporation upon addition of PPAR agonists
Tris-Hcl [pH 8] and 150 mM NaCl in 50% glycerol). Histones wereto RB/ MEFs, in which PPAR is not inhibited by RB.
then separated in SDS-PAGE, electrotransfered, and blotted with
The enhanced expression of PPAR target genes and anti-acetylated histone H4 (Lys9) antibody.
the stimulation of adipocyte differentiation observed
upon HDAC inhibition is also consistent with such an Protein and RNA Expression
inhibitory effect of RB-HDAC3 on PPAR-mediated adi- SDS-PAGE and electrotransfer were performed as described (Roc-
pogenesis. Additional evidence for a negative role of chi et al., 2001). The membranes were blocked overnight in blocking
buffer (20 mM Tris, 100 mM NaCl, 1% Tween 20, and 10% skimmedRB is the predominance of phosphorylated and, thus,
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milk). Filters were first incubated for 4 hr at 21	C with primary anti- activated receptor  bypasses the function of the retinoblastoma
protein in adipocyte differentiation. J. Biol. Chem. 274, 2386–2393.body and then for 1 hr at 21	C with a peroxidase conjugate second-
ary antibody. The complex was visualized with 4-chloro-1-naphtol. Higgins, C., Chatterjee, S., and Cherington, V. (1996). The block of
RNA isolation, reverse transcription, and multiplex RT-PCR (Hansen adipocyte differentiation by a C-terminally truncated, but not by full-
et al., 1999) or northern blot hybridization (Rocchi et al., 2001) were length, simian virus 40 large tumor antigen is dependent on an intact
performed as described. retinoblastoma susceptibility protein family binding domain. J. Virol.
70, 745–752.
Radioligand Binding Assay Johansson, L., Thomsen, J.S., Damdimopoulos, A.E., Spyrou, G.,
GST-PPAR fixed on Sepharose beads was incubated for 4 hr at Gustafsson, J.A., and Treuter, E. (1999). The orphan nuclear receptor
4	C in 10 mM Tris (pH 8), 50 mM KCl, and 1 mM DTT with 5 nM 3H- SHP inhibits agonist-dependent transcriptional activity of estrogen
rosiglitazone (1.4–220 nM for saturation analysis) in the absence or receptors ERalpha and ERbeta. J. Biol. Chem. 274, 345–353.
presence of either cold rosiglitazone or the indicated concentrations Lampen, A., Carlberg, C., and Nau, H. (2001). Peroxisome prolifera-
of HDAC inhibitors. This was followed by filtration on Whatman GF/C tor-activated receptor delta is a specific sensor for teratogenic val-
filters. proic acid derivatives. Eur. J. Pharmacol. 431, 25–33.
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